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The Heart of Diabetes* pretreatment also improved survival in the cecal ligation and puncture model. Many human studies suggest a benefit of chronic prior statin use and improved outcome with infection, although with acutely administered statins the results are far less certain (11) . Ghosh et al (8) report two combined clinical trials, simvastatin 40 mg orally or placebo once daily in statin-naive subjects. No toxicity was seen, and a reduction in circulating Angpt-2 levels was seen together with a trend toward reduced inflammatory mediators such as tumor necrosis factor-α, soluble vascular cell adhesion molecule 1, and sE-selectin. All of this looks promising, but we have to put this in the context of a recent landmark trial. In a multicenter randomized trial, rosuvastatin was shown to have no benefit in sepsis-associated ARDS; in fact, the study was terminated early for futility (12) .
Do we put statins back on the shelf next to drotrecogin alfa, or is there still more to unravel in the statin and sepsis story? Several variables that may affect the clinical efficacy of statins for the treatment of sepsis may be worth further exploration. These include how to administer and when to administer the statin, and how to select a target population.
Statins undergo a significant first-pass effect that may be of benefit to target the liver to lower cholesterol but substantially reduces bioavailability to other organs including the lung. To target the pulmonary endothelium, administration may have to be by the parenteral route.
As Ghosh et al (8) conclude, and as the animal models and most clinical studies have shown, intervention needs to be early, in fact before the onset of illness. So can we identify a population in which the sepsis syndrome will develop early enough that they may benefit from statins? Can elevated Angpt-2 levels identify a patient population that may be targeted with statin therapy?
Perhaps those with high circulating Angpt-2 levels may be the ones to target and treat, or perhaps by then it is already too late. this issue of Critical Care Medicine, Jiang et al (2) examined the cardiac expressions of those three receptors in rats with genetically induced obesity and diabetes. The rats genetically carried fa, a "fatty" allele for a nonfunctional leptin receptor. Lean healthy animals were heterozygotes, carrying one nonfunctional allele but also one for functioning receptor. Obese rats were homozygotes with two copies of the nonfunctional fa allele. Those obese fa/fa animals exhibited hyperphagia and hyperlipidemia and high circulating leptin, but they were not hyperglycemic. A third group had diabetes; they were also homozygous for fa, but for an unknown additional genetic reason, they suffered hyperglycemia.
The isolated left ventricular papillary muscles of healthy, obese, diabetic rats were each stimulated with isoproterenol in vitro (2) . Maximum isometric active forces were mechanically determined, and the extents of β-receptor expressions in the muscles were measured by Western blot.
Both obese and diabetic rats evinced an attenuated inotropic response compared with lean rats, with the diminished E xamining the various potencies of six agonists at several organs, Ahlquist ( Fig. 1 ) proposed in 1948 that there are αand β-receptors for sympathomimetic agents (1). Of these, the β-receptors are now subdivided into three types. In response more pronounced in diabetics (2) . Immunoblotting explained the dysfunction by revealing reduced levels of both β1and β2-adrenoceptors on the myocytes. Accordingly, the obese and diabetic rats were functionally "β-blocked." (β3receptors were preserved, but these are inhibitory in the heart. One wonders about the cardiac glucagon receptors.)
Functional β-blockade has been previously seen in rats following streptozotocin-induced pancreatic damage (3). Streptozotocin-induced hyperglycemia might mimic type 1 diabetes, whereas the genetic diabetes of Zucker rats might better mimic type 2. Of note, there is overexpression of the cardiodepressant β3-receptors in the streptozotocin rat model (4) .
It is interesting to consider the role played by leptin and its nonfunctional receptor in the hyperlipidemia of the fa/fa obese Zucker rats and the hyperglycemia of the fa/fa diabetic Zucker rats. Leptin is incompletely understood. It was initially discovered as a fat-derived peptide that signals the hypothalamus to reduce desire for food. However, many cell types produce the peptide, and there are receptors in addition to the hypothalamic ones. Humans with congenital or acquired generalized deficiency of fat tissue (lipodystrophy) are low in circulating leptin and exhibit disturbed lipid and sugar metabolism, including insulin resistance. In 2014, the U.S. Food and Drug Administration approved metreleptin, a recombinant peptide nearly identical to leptin, to treat these problems of lipodystrophy. Leptin supplementation reduces hemoglobin glycation, fasting glucose, and triglycerides in such patients (5).
A number of studies have focused on the role of leptin in inflammation and insulin resistance in critical illness. Leptin levels initially rise during sepsis but subsequently decline (6, 7) . Leptin promotes the initial inflammatory response that often serves to protect the host. Low serum leptin levels in critically ill patients have been associated with a higher risk of death, and it has been suggested that leptin deficiency may increase mortality during sepsis (8) (9) (10) (11) . Indeed, as mentioned by Jiang et al (2), there is a controversial "obesity paradox" in which overweight patients, perhaps more able to generate leptin, are better able than lean patients to cope with some physiologic challenges (12, 13) . Leptin administration may thus have a therapeutic role in critical illness.
Although the unhealthy Zucker mutant rats have high circulating leptin (2), the reason is presumably a nonfunctional receptor. Therefore, they are deficient in leptin action. Giving leptin to Zucker rats may not help them. However, mice with genetic lesions of leptin production exhibit disrupted β-adrenergic signaling and myocyte contractility. Such mice do improve upon leptin administration (14) .
It will be interesting to see if leptin supplementation might improve any β-adrenergic dysfunction of critically ill patients suffering obesity and/or diabetes. The eventual availability of leptin ought to prompt examination of its action in acute inflammation, sepsis, trauma, circulatory shock, and other critical illnesses. Unfortunately, metreleptin is not necessarily a benign leptin supplement. The recombinant protein carries an extra amino acid residue and is slightly antigenic. In patients who have leptin-producing cells and endogenous circulating leptin molecules, it is feared that metreleptin can induce antileptin antibodies (15).
Although both strains of sick Zucker rats carry homozygous defects (fa/fa) in the leptin receptor, there are some puzzles (2) . For instance, circulating leptin is elevated in fa/fa animals, but the obese nondiabetic rats have much higher levels of circulating leptin than do the diabetic ones. Furthermore, the diabetic rats, although called "obese diabetic," were not heavier than the lean (fa/+) rats (2) . It will be interesting to further characterize the genetic feature that converts obese normoglycemic fa/fa rats into lighter but diabetic fa/fa rats. It will also be of interest to determine why the transformation to the diabetic state lowers the circulating leptin levels of receptor-lacking rats. There is still much to learn about Zucker rats and their bipedal congeners. S eptic acute kidney injury (AKI) is a major clinical syndrome for which no effective treatment exists. Sepsis-induced systemic inflammation promotes several biological responses, such as apoptotic and necroptotic cell death in various tissues, including the kidneys. Dying cells release or expose cellular components, so-called damageassociated molecular patterns, which further amplify the inflammatory response and tissue damage (1) . Endogenous small RNA molecules, so-called microRNAs (miRNAs), appear to be key players in the regulation of cell survival in this setting and may be potential targets for prevention and treatment of septic AKI (2) .
In this issue of Critical Care Medicine, Jia et al (3) demonstrate that preconditioning with xenon, a noble gas found in very low concentration in the air we breathe, attenuates septic AKI and liver injury via inhibition of apoptosis and mitigation of the systemic inflammatory response. In an experimental study, mice were treated with either 70% xenon or 70% nitrogen for 2 hours before induction of sepsis by intraperitoneal injection of Escherichia coli lipopolysaccharide (LPS). Functional (doubling of serum creatinine) and morphological evidence of AKI was seen within 24 hours after the LPS injection. In addition, using real-time reverse transcription polymerase chain reaction, the authors discovered that proinflammatory interleukin (IL)-6 and tumor necrosis factor (TNF)-α messenger RNA (mRNA) and anti-inflammatory IL-10 mRNA were up-regulated in the kidney parenchyma, accompanied by increased cytokine levels within the kidney tissue as well as in the circulation. In parallel, renal cell apoptosis, as detected by transferase-mediated dUTP nick-end labeling (TUNEL) staining, markedly increased together with renal cellular synthesis of pro-and antiapoptotic factors.
Inflammation and apoptosis are not disconnected entities. In fact, Jia et al (3) confirm that sepsis triggers the powerful inflammatory programmed cell death protein 4 (PDCD4)nuclear factor (NF)-κB pathway as well as the apoptotic phosphatase and tensin homolog deleted on chromosome 10 (PTEN)-cleaved caspase-3 pathway. Furthermore, they demonstrate that a member of the miRNA family with a strong protective antiapoptotic effect, namely miR-21, is a key player in the regulation of both pathways.
Before the current study, Jia et al (3) and other investigators had already demonstrated that xenon stimulates miR-21 expression and protects against ischemia-reperfusion and nephrotoxic kidney injuries (4-6). In the present study, they
